MedTrace Logo

Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans

NCT05294263 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-08-27

No results posted yet for this study

Summary

After initial eligibility screening, Veterans who use both cannabis and tobacco will be randomly assigned to receive either varenicline (Chantix) or placebo for 12 weeks. Participants will attend weekly visits, in person or remotely, to provide breath and urine samples for testing, fill out questionnaires, and meet with study staff about medication compliance.

Conditions

  • Tobacco Use Disorder
  • Cannabis Use Disorder

Interventions

DRUG

Varenicline

Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype

DRUG

Placebo

Matching, inactive medication

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Aimee L. Mcrae-Clark, PharmD · Ralph H. Johnson VA Medical Center, Charleston, SC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2024-07-17
Completion
2024-07-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294263 on ClinicalTrials.gov